Pasithea Therapeutics Corp Earnings

The next earnings date for Pasithea Therapeutics Corp has not yet been scheduled.

Analyst Estimates of Pasithea Therapeutics Corp Earnings

No Results.
Report DateEstimated Earnings Per Share
No Results.

What is an Earnings Date

An earnings date is typically considered to be the date that a company publicly announces its earnings. Many companies in the US stock market do earnings announcements once per quarter.

Earnings announcements are typically accompanied by commentary from the company that explains the earnings performance and speaks to future earnings prospects.

Earnings announcements can cause a company’s stock price to change abruptly, so earnings dates are closely monitored by some investors.

Pasithea Therapeutics Corp Earnings: Historical

Report DateBefore/After MarketEarnings Per ShareSurprise %
12/27/2024After Market$-2.87---
08/11/2024After Market$-3.71---
05/14/2024After Market$-3.70---
03/28/2024After Market$-4.85-2,450.84%
12/29/2023After Market$-0.1420.22%
08/11/2023After Market$-0.1415.29%
05/31/2023---$-0.170.00%
03/01/2023---$-0.180.00%
11/14/2022---$-0.17-21.43%
08/15/2022After Market$-0.110.00%
05/16/2022After Market$-0.07-250.00%
03/30/2022After Market$0.12340.00%
11/18/2021After Market$-0.12---
09/16/2021After Market$-0.05---
06/30/2021---$-0.09---
03/31/2021---$-0.07---
09/30/2020---$-0.00---

More About Pasithea Therapeutics Corp

Country
USA
Full Time Employees
4

Pasithea Therapeutics Corp., a clinical-stage biotechnology company, focuses on the discovery, research, and development of treatments for central nervous system (CNS) disorders, RASopathies, and cancers. Its lead product candidate is PAS-004, a next-generation macrocyclic mitogen-activated protein kinase, or MEK inhibitor to treat a range of RASopathies, including neurofibromatosis type 1 (NF1); MAPK pathway-driven tumors, such as BRAFv600 and BRAF fusion tumors; and ETS2 driven diseases, including inflammatory bowel disease (IBD), primary sclerosing cholangitis, and ankylosing spondylitis. The company's lead development candidate is PAS-003, to treat amyotrophic lateral sclerosis. It also intends to develop PAS-001, to treat schizophrenia. Pasithea Therapeutics Corp. was incorporated in 2020 and is headquartered in Miami Beach, Florida.

Pasithea Therapeutics Corp Earnings” Can Refer to the Pasithea Therapeutics Corp Earnings Date

Some people say “Pasithea Therapeutics Corp earnings” as a shortform way to refer to the earnings date.

For example, someone might say, “I plan to hold my Pasithea Therapeutics Corp position through earnings.” That typically means the person is going to hold their position through the upcoming earnings date.

Owning Pasithea Therapeutics Corp Stock on the Earnings Date

If you own Pasithea Therapeutics Corp stock (KTTA) on the earnings date, then you will be exposed to the potential price volatility that often accompanies earnings announcements.

A company’s earnings typically have a big impact on its stock price, which explains why the stock price for Pasithea Therapeutics Corp might exhibit major fluctuations on the day of the earnings announcement. The price fluctuations can go in either direction (up or down), representing a larger potential investment risk and reward than many other days of the year.

There is often a big audience of investors involved with trading Pasithea Therapeutics Corp shares of stock on its earnings day. This means there is typically more trading volume, liquidity, and price volatility on the day earnings are announced.

These features are attractive to some types of active traders who are looking for stocks that exhibit large price movements and substantial volume.

Learning More Pasithea Therapeutics Corp Earnings

You can contact us any time if you would like to ask questions about Pasithea Therapeutics Corp earnings or anything else related to the stock market.